药品不良事件的经济成本研究案例分析

中国药物警戒 ›› 2015, Vol. 12 ›› Issue (10): 607-610.

• 药品不良反应监测与评价专栏 • 上一篇下一篇

药品不良事件的经济成本研究案例分析

高建超, 李岚, 夏东胜, 田春华

国家食品药品监督管理总局药品评价中心，北京 100045

收稿日期:2015-09-15 修回日期:2015-12-07 出版日期:2015-10-08 发布日期:2015-12-07
作者简介:高建超，男，博士，主管药师，药品不良反应监测与安全性再评价。

Analysis of the Case Study on the Economic Cost of Adverse Drug Events

GAO Jian-chao, LI Lan, XIA Dong-sheng, TIAN Chun-hua

Center for Drug Reevaluation, CFDA, Beijing 100045, China

Received:2015-09-15 Revised:2015-12-07 Online:2015-10-08 Published:2015-12-07

摘要/Abstract

摘要： 药品不良事件不仅损害患者的身体健康，而且给患者和社会带来沉重的经济负担，对药品不良事件的经济成本进行研究不仅能减轻患者的经济负担和国家医疗保障系统的财政压力，还能为临床合理用药和制定最佳疾病防治措施提供科学依据。本文介绍了药品不良事件分类及其经济成本的构成，并通过分析经济成本的研究案例来总结不同的经济成本研究方法，并提出降低药品不良事件经济成本的建议。

关键词: 药品不良事件, 经济学成本

Abstract: Adverse drug events injure the health of patients and impose heavy economic burden on patients and society. The study on the economic cost of adverse drug events not only reduces the economic burden on patients and the national medical care system, but also provides scientific basis for rational drug use and developing optimal disease control measures. We introduced the classification of drug adverse event and the composition of its economic cost, summarized different economic cost research methods by analyzing the case studies of economic cost, and finally proposed advices for reducing the economic costs of adverse drug events.

Key words: adverse drug events, economic cost

中图分类号:

高建超, 李岚, 夏东胜, 田春华. 药品不良事件的经济成本研究案例分析[J]. 中国药物警戒, 2015, 12(10): 607-610.

GAO Jian-chao, LI Lan, XIA Dong-sheng, TIAN Chun-hua. Analysis of the Case Study on the Economic Cost of Adverse Drug Events[J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 607-610.

参考文献

[1] International drug monitoring. The role of the hospital[J].World Health Organ Tech Rep Ser, 1969,425: 5-24.
[2] Rodríguez-Monguió R, Otero M J, Rovira J.Assessing the economic impact of adverse drug effects[J].Pharmacoeconomics, 2003,21(9): 623-650.
[3] 孟玉芳,茅宁莹. 药物经济学在我国医药产业的应用与发展趋势[J].中国现代药物应用, 2007, 28(9): 30-31.
[4] Gyllensten H, Rehnberg C, J nsson A K, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey[J]. BMJ Open, 2013,3(6): e002574.
[5] Lahue B J, Pyenson B, Iwasaki K, et al.National burden of preventable adverse drug events associated with inpatient injectable medications: healthcare and medical professional liability costs[J]. Am Health Drug Benefits, 2012, 5(7): 1-10.
[6] 陈崇泽.140例药品不良反应报告与成本分析[J]. 中国药物警戒, 2010,7(9):561-563.
[7] Powe N R, Davidoff A J, Moore R D, et al. Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography[J].J Am Coll Cardiol,1993, 21(7):
1701-1709.
[8] 北京大学中国医药经济研究中心药品不良反应经济成本研究课题组.药品不良反应直接经济成本研究[J]. 中国药物经济学, 2007, (2): 30-35.
[9] Hannan E L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations[J].JACC Cardiovasc Interv. 2008, 1(3):211-217.
[10] 肖永红,侯芳,王进,等. 抗菌药物不良反应的社会与经济后果调查[J]. 中国卫生经济, 2010,29(5): 94-96.
[11] 苏长海.我院因药品不良反应导致患者再入院的发生率和严重性评价[J]. 中国药房, 2011,22(22): 2080-2083.
[12] Hakkarainen K M, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions-a meta-analysis[J]. PLoS One, 2012, 7(3): e33236.
[13] Rottenkolber D, Schmiedl S, Rottenkolber M, et al.Adverse drug reactions in Germany: direct costs of internal medicine hospitaliz-
ations[J]. Pharmacoepidemiol Drug Saf, 2011, 20(6): 626-634.
[14] Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients[J]. BMJ, 2004, 329(7456): 15-19.
[15] Wu C, Bell C M, Wodchis W P. Wodchis. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study[J]. Drug Saf, 2012, 35(9): 769-781.
[16] Patel K J, Kedia M S, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study[J]. BMC Clin Pharmacol, 2007, 7: 8.
[17] Chan A L, Lee H Y, Ho C H, et al. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study[J]. Curr Ther Res Clin Exp, 2008, 69(2): 118-129.
[18] Carrasco-Garrido P, de Andrés L A, Barrera V H, et al. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006)[J]. BMC Health Serv Res, 2010, 10: 287.
[19] Patsopoulos NA. A pragmatic view on pragmatic trials[J].Dialogues Clin Neurosci. 2011,13(2):217-224.
[20] Zwarenstein M, Treweek S, Gagnier J J, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement[J]. BMJ. 2008, 337:a2390.
[21] 孙世光,闰荟,王苏会,等. 药物经济学在药品不良反应评价中的应用[J]. 中国药物经济学，2010, 4(6): 36-40.

药品不良事件的经济成本研究案例分析

Analysis of the Case Study on the Economic Cost of Adverse Drug Events

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈亚昆, 门鹏, 王攀. 基于FAERS数据库的4种磷酸二酯酶5抑制剂安全性分析[J]. 中国药物警戒, 2023, 20(6): 691-696.
[2]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[3]	郝晓慧, 张萍, 武璐璐, 王丽华. 基于FAERS数据库的枸橼酸伊沙佐米胶囊安全信号挖掘研究[J]. 中国药物警戒, 2023, 20(12): 1427-1431.
[4]	张玄羿, 孔文强, 钟红, 邓慧远, 舒云峰. 基于FAERS数据库挖掘阿比特龙不良事件信号研究[J]. 中国药物警戒, 2023, 20(10): 1148-1153.
[5]	钱佩佩, 曹凯, 徐炳欣, 应亚宾, 赵宁珂, 赵亮. 基于JADER数据库的奈玛特韦/利托那韦不良事件信号检测与分析[J]. 中国药物警戒, 2023, 20(10): 1154-1158.
[6]	张弛. PCSK9抑制剂阿利罗库单抗不良事件信号发掘[J]. 中国药物警戒, 2022, 19(6): 684-691.
[7]	周瑞欧, 季欢欢, 龚莉, 张妮, 宋林. 基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价[J]. 中国药物警戒, 2022, 19(2): 205-209.
[8]	韩忠灵, 夏菊梅, 王轶睿, 杨立, 滕亮. 全面触发工具在肾移植受者免疫抑制药品不良事件监测中的运用[J]. 中国药物警戒, 2021, 18(3): 265-270.
[9]	张伟威, 王娜. 全面触发工具在老年住院患者药品不良事件监测中的研究[J]. 中国药物警戒, 2021, 18(1): 56-63.
[10]	吴文利, 刘佳妮, 陆钊罡, 景晶, 王健, 王基云, 王晓旭. 双氯芬酸钠盐酸利多卡因药品不良反应/事件分析[J]. 中国药物警戒, 2020, 17(8): 508-512.
[11]	潘道苇, 宛蕾. 应用CHPS初步监测皮下注射国产硼替佐米的安全性[J]. 中国药物警戒, 2020, 17(12): 913-916.
[12]	栗啸阳, 郭代红, 刘思源, 杨鸿溢, 姚翀, 齐榛. 注射用头孢哌酮钠舒巴坦钠相关血小板减少的自动监测研究[J]. 中国药物警戒, 2020, 17(12): 890-893.
[13]	吴文利, 景晶, 陆钊罡, 张桂香, 王健, 王晓旭, 王基云. 某院182例严重药品不良反应/事件分析[J]. 中国药物警戒, 2020, 17(11): 803-807.
[14]	徐家玥, 胡巧织, 徐铤. 运用全面触发工具监测心理卫生疾病住院患者药品不良事件[J]. 中国药物警戒, 2019, 16(6): 352-359.
[15]	葛文超. 安徽省药品不良事件聚集性信号分析[J]. 中国药物警戒, 2019, 16(2): 123-125.